Semaglutide tablets are primarily prescribed to improve glycemic control in adults with type 2 diabetes. They work through several biological mechanisms that help regulate blood glucose, particularly after meals.
The medication stimulates insulin release when blood glucose levels are elevated. It also reduces glucagon secretion, a hormone that signals the liver to release stored glucose. These combined effects help maintain better glucose regulation.
Important clinical applications include:
Type 2 diabetes management: Used alongside diet and exercise to improve blood glucose control.
Glycated hemoglobin reduction: Helps lower HbA1c levels, which reflect average blood glucose over approximately three months.
Cardiovascular risk considerations: Semaglutide has demonstrated cardiovascular benefits in certain populations and formulations. The evidence and approved indications should be considered separately for oral and injectable products.
Weight management effects: May reduce appetite and food intake, contributing to weight reduction in some patients. Oral diabetes formulations should not automatically be considered approved weight-loss treatments.
Combination therapy: May be prescribed with other diabetes medications when additional glucose control is required.
Treatment decisions depend on individual health conditions, existing medications, and clinical requirements.
Oral semaglutide has specific administration requirements because food and beverages can significantly affect its absorption. Patients are generally instructed to take the tablet on an empty stomach after waking up.
The tablet should be swallowed whole with a small amount of plain water. Patients should wait at least 30 minutes before eating, drinking, or taking other oral medications. Following these instructions helps improve medication absorption and treatment consistency.
Several safety considerations are important during treatment:
Gastrointestinal effects: Nausea, vomiting, diarrhea, constipation, and abdominal discomfort are commonly reported.
Hypoglycemia: The risk of low blood glucose may increase when semaglutide is combined with insulin or sulfonylureas.
Pancreatitis: Severe or persistent abdominal pain requires immediate medical assessment because pancreatitis has been reported.
Diabetic retinopathy: Patients with existing diabetic eye disease may require monitoring, particularly when blood glucose improves rapidly.
Kidney concerns: Dehydration resulting from persistent vomiting or diarrhea can contribute to kidney problems.
Thyroid tumor warning: Semaglutide carries a boxed warning in the United States concerning thyroid C-cell tumors observed in rodents. It is contraindicated in people with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 under US prescribing information.
Healthcare professionals assess medical history, treatment response, and possible interactions before recommending semaglutide tablets. Regular follow-up appointments help evaluate glucose levels, tolerability, and the need for treatment adjustments.